Xavier Matias-Guiu , Sigurd Lax , Maria Rosaria Raspollini , Jose Palacios , Wenxin Zheng , Congrong Liu , Louise de Brot , Leonardo Lordello , David Hardisson , David Gaffney , David Mutch , Giovanni Scambia , Carien L. Creutzberg , Christina Fotopoulou , Jonathan S. Berek , Nicole Concin
{"title":"FIGO 2023 子宫内膜癌分期,如果不是现在,是何时?","authors":"Xavier Matias-Guiu , Sigurd Lax , Maria Rosaria Raspollini , Jose Palacios , Wenxin Zheng , Congrong Liu , Louise de Brot , Leonardo Lordello , David Hardisson , David Gaffney , David Mutch , Giovanni Scambia , Carien L. Creutzberg , Christina Fotopoulou , Jonathan S. Berek , Nicole Concin","doi":"10.1016/j.ejca.2024.115115","DOIUrl":null,"url":null,"abstract":"<div><div>Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115115"},"PeriodicalIF":7.6000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FIGO 2023 staging for endometrial cancer, when, if it is not now?\",\"authors\":\"Xavier Matias-Guiu , Sigurd Lax , Maria Rosaria Raspollini , Jose Palacios , Wenxin Zheng , Congrong Liu , Louise de Brot , Leonardo Lordello , David Hardisson , David Gaffney , David Mutch , Giovanni Scambia , Carien L. Creutzberg , Christina Fotopoulou , Jonathan S. Berek , Nicole Concin\",\"doi\":\"10.1016/j.ejca.2024.115115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.</div></div>\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"213 \",\"pages\":\"Article 115115\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924017222\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924017222","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
FIGO 2023 staging for endometrial cancer, when, if it is not now?
Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.